Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, and Veterans Administration Medical Center, Lexington, Kentucky.
Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas.
Am J Cardiol. 2018 Oct 15;122(8):1345-1351. doi: 10.1016/j.amjcard.2018.07.001. Epub 2018 Jul 19.
Catheter ablation (CA) is an effective treatment for ventricular arrhythmias (VA), with a potential for complications. The presence of structural heart disease (SHD) is associated with a higher complication rate although there is no data comparing CA of VA between patients with SHD and those without. We aimed to compare trends, morbidity, and mortality associated with real world practice of CA for VA (ventricular tachycardia and premature ventricular contraction) based on the presence of SHD. Using weighted sampling in the National Inpatient Sample database, we collected and compared characteristics and outcomes of patients with or without SHD that underwent CA of VA. Among 34,907 patients that underwent CA for VA (1999-2013), 18,014 (51.6%) had SHD. Major and all complications occurred among 1,135/18,014 (6.3%) and 2139/18,014 (11.9%) patients with SHD respectively compared with 355/16,893 (2.1%) and 739/16,893 (4.4%) for patients without SHD, p < 0.001 for both comparisons. Furthermore, 452/18,014 (2.51%) with SHD died versus 20/16,893 (0.12%) without SHD, p < 0.001. Heart failure was associated with an odds ratio (OR) of 3.09 for major complications (95%CI: 1.53-6.27, p = 0.002) for patients with SHD while coronary artery disease OR for major complications was 2.47 (95%CI: 1.44-4.23, p = 0.001) for patients without SHD. There was a significant increase in major complications over the 15-year study period in patients with SHD, p < 0.001. In conclusion, the presence of SHD during CA for VA increased the complication rate of major and any complications by approximately threefold for both and the hospital mortality by >20-fold compared with patients without SHD.
导管消融(CA)是治疗室性心律失常(VA)的有效方法,但存在潜在并发症。结构性心脏病(SHD)的存在与更高的并发症发生率相关,尽管尚无数据比较 SHD 患者和非 SHD 患者的 CA 治疗 VA(室性心动过速和室性期前收缩)的结果。我们旨在比较基于 SHD 存在的真实世界实践中,CA 治疗 VA 的趋势、发病率和死亡率。使用国家住院患者样本数据库中的加权抽样,我们收集并比较了有或无 SHD 的患者接受 VA 的 CA 治疗的特征和结局。在 34907 例接受 VA 的 CA 治疗的患者(1999-2013 年)中,有 18014 例(51.6%)有 SHD。有 SHD 的患者中,主要并发症和所有并发症的发生率分别为 1135/18014(6.3%)和 2139/18014(11.9%),而无 SHD 的患者中,主要并发症和所有并发症的发生率分别为 355/16893(2.1%)和 739/16893(4.4%),两组比较均 P<0.001。此外,18014 例有 SHD 的患者中有 452 例(2.51%)死亡,而 16893 例无 SHD 的患者中有 20 例(0.12%)死亡,两组比较均 P<0.001。心力衰竭与 SHD 患者的主要并发症的优势比(OR)为 3.09(95%CI:1.53-6.27,P=0.002),而无 SHD 的患者中,冠心病的 OR 为 2.47(95%CI:1.44-4.23,P=0.001)。在 15 年的研究期间,有 SHD 的患者的主要并发症发生率显著增加,P<0.001。总之,VA 的 CA 治疗中存在 SHD,使主要和任何并发症的并发症发生率增加了近 3 倍,与无 SHD 的患者相比,住院死亡率增加了 20 多倍。